View ValuationPell Bio-Med Technology 将来の成長Future 基準チェック /06現在、 Pell Bio-Med Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長35.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).お知らせ • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city TaiwanNew Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).お知らせ • May 06Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025Reported Earnings • Mar 18Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023)Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023).お知らせ • Mar 12Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwanお知らせ • Mar 04Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).分析記事 • Feb 05Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023)Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023).お知らせ • Nov 01Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023).お知らせ • Aug 06Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024分析記事 • Jul 22Pell Bio-Med Technology (TWSE:6949) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • May 29New major risk - Revenue and earnings growthRevenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k).お知らせ • Mar 27PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pell Bio-Med Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TWSE:6949 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202626-425-567-336N/A12/31/202531-424-509-281N/A9/30/202530-374-572-269N/A6/30/202527-356-628-288N/A3/31/202527-380-578-266N/A12/31/202420-389-524-260N/A9/30/202418-386-367-243N/A6/30/202418-404-197-186N/A3/31/202418-425-207-188N/A12/31/202318-399-196-180N/A9/30/202320-361-182-172N/A6/30/202320-310-189-178N/A3/31/202319-238-177-170N/A12/31/202217-230-169-161N/A12/31/202114-189-122-108N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6949の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6949の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6949の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6949の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6949の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6949の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 17:30終値2026/05/28 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pell Bio-Med Technology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).
Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).
お知らせ • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city Taiwan
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).
Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).
お知らせ • May 06Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025
Reported Earnings • Mar 18Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023)Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023).
お知らせ • Mar 12Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwan
お知らせ • Mar 04Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
分析記事 • Feb 05Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023)Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023).
お知らせ • Nov 01Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024
Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023).
お知らせ • Aug 06Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024
分析記事 • Jul 22Pell Bio-Med Technology (TWSE:6949) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • May 29New major risk - Revenue and earnings growthRevenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k).
お知らせ • Mar 27PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024.